Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant

Clinical Pharmacokinetics

Volumn 39, Issue SUPPL. 1, 2000, Pages 17-22

  Mackie, Alison E ^a   McDowall, Jo E ^b   Ventresca, Pietro ^b   Bye, Alan ^b   Falcoz, Christine ^b   Daley Yates, Peter T ^b  

^a ELI LILLY AND COMPANY   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROFLUOROCARBON; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; HYDROCORTISONE; PROPELLANT;

ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; MALE; METERED DOSE INHALER; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0033674210     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039001-00003     Document Type: Article

References (5)

1. Brindley C, Falcoz C, Mackie AE, et al. Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler®, Diskus®, and metered-dose inhaler in healthy volunteers. Clin Pharmacokinet 2000; 39 Suppl. 1: 1-8
2. Rowland M, Tozer TN, editors. Clinical pharmacokinetics: concepts and applications. 3rd ed. Philadelphia: Williams & Wilkins, 1995
3. Jones B, Kenward MG. Design and analysis of cross-over trials. London: Chapman and Hall, 1989
4. Kunka R, Andrews S, Pimazzoni M, et al. Dose proportionality of fluticasone propionate from hydrofluoroalkane pressurised metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med 2000; 94 Suppl. B: S10-16
5. Daley-Yates PT, Tournant J, Kunka RL. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma. Clin Pharmacokinet 2000; 39 Suppl. 1: 39-45